$ABBV (AbbVie Inc.) Support & Resistance Levels, AI Price Target & Institutional Flow.
Today, $ABBV (AbbVie Inc.) trades at $286.20 (+0.94%) with a 64/100 Momentum Pulse (BULLISH FLOW) and 14D RSI at 46.7 (NEUTRAL CONSOLIDATION (46.7)). Unlock the live $ABBV support and resistance levels, 30D Put Wall floor, 20D SMA pivot, Call Wall ceiling, dark pool flow, and locked 1-Month AI Price Target (+14.2% upside corridor) below—or create a free 24/7 AI quant agent to guard $ABBV.
Spot Price: $286.20 | 30-Day Support Floor: $272.70 (4.72% above) | 10-Day EMA: $290.00 | 20-Day SMA Pivot: $290.44 | 30-Day Resistance Ceiling: $295.03 (3.09% below) | 14-Day RSI: 46.7 (NEUTRAL CONSOLIDATION (46.7)) | 30-Day Trading Corridor: 8.19% span. Value and mean-reversion buyers in AbbVie Inc. ($ABBV) are monitoring the $272.70 30-day mechanical support floor (spot price at $286.20 sits 4.72% above support with 14-day RSI at 46.7 (NEUTRAL CONSOLIDATION (46.7))). Reclaiming the 10-day EMA ($290.00) and 20-day SMA pivot ($290.44) is the primary technical trigger to ignite a move back toward the $295.03 resistance ceiling.
$ABBV (AbbVie Inc.) Live Key Levels, RSI & Valuation Matrix
| $ABBV Technical Metric | Live Value | $ABBV Fundamental / Regime Metric | Live Status |
|---|---|---|---|
| Live Spot Price (24h Change) | $286.20 (+0.94%) | Market Capitalization | $505.75B |
| 30-Day Mechanical Support Floor (Put Wall) | $272.70 (4.72% cushion) | 52-Week High / Low Range | $190.75 – $302.93 |
| 20-Day Simple Moving Average (20D SMA) | $290.44 | Trailing P/E Ratio & Dividend Yield | 48.90x • Yield: 2.42% |
| 10-Day Exponential Moving Average (10D EMA) | $290.00 | Average Daily Volume (Liquidity) | 6.19M shares |
| 30-Day Resistance Ceiling (Call Wall) | $295.03 (3.09% upside to test) | Next Scheduled Earnings / Catalyst Window | 2026-10-30 |
| 14-Day Relative Strength Index (RSI) | NEUTRAL CONSOLIDATION (46.7) | Saku Momentum Pulse & Health Rating | 64/100 Momentum • 74/100 Health |
Should You Buy $ABBV Stock Now or Wait?
Value and mean-reversion buyers in AbbVie Inc. ($ABBV) are monitoring the $272.70 30-day mechanical support floor (spot price at $286.20 sits 4.72% above support with 14-day RSI at 46.7 (NEUTRAL CONSOLIDATION (46.7))). Reclaiming the 10-day EMA ($290.00) and 20-day SMA pivot ($290.44) is the primary technical trigger to ignite a move back toward the $295.03 resistance ceiling.
$ABBV (AbbVie Inc.) is currently trading below its 20-day simple moving average ($290.44) after a +2.43% 30-day move. If buyers fail to defend the 30-day mechanical support floor at $272.70 (4.72% above current spot), negative dealer gamma hedging can accelerate downside discovery toward the lower end of its 52-week range ($190.75).
$ABBV Support & Resistance, Institutional Flow & Catalysts.
$ABBV Support & Resistance
Spot Price: $286.20 | 30-Day Support Floor: $272.70 (4.72% above) | 10-Day EMA: $290.00 | 20-Day SMA Pivot: $290.44 | 30-Day Resistance Ceiling: $295.03 (3.09% below) | 14-Day RSI: 46.7 (NEUTRAL CONSOLIDATION (46.7)) | 30-Day Trading Corridor: 8.19% span.
$ABBV Institutional & Whale Flow
Institutional order flow for $ABBV (averaging 6.19M shares daily volume) is concentrated between the $272.70 Put Wall support zone and $295.03 Call Wall resistance ceiling, with a live Saku Fundamental Health score of 74/100.
$ABBV Catalyst Outlook
Next scheduled earnings window for AbbVie Inc. ($ABBV): 2026-10-30. Latest tracked headline from 247wallst.com: "$500,000 in AbbVie and Gilead Could Pay More Than $11,000 a Year in Dividends".
Latest $ABBV (AbbVie Inc.) Breaking News & Headlines
About AbbVie Inc. ($ABBV)
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio.
Saku's quantitative engine continuously monitors $ABBV's 30-day mechanical support floor ($272.70), 20-day simple moving average ($290.44), and 30-day resistance ceiling ($295.03) alongside off-exchange dark pool block prints and SEC filings.
Hatch Your Own 24/7 AI Co-Pilot to Guard $ABBV.
Step inside the 3D Quant Sanctuary and claim Workstation #4 to hatch your personal AI analyst (Momentum, Dip-Buyer, or Value & Catalyst style). Your agent monitors $ABBV 24/7 with locked 1-month price targets, hard stop-loss tripwires, 3x/day shift briefings, and live Koi Bridge debates.

What are the live 30-day support and resistance levels for $ABBV (AbbVie Inc.)?
Spot Price: $286.20 | 30-Day Support Floor: $272.70 (4.72% above) | 10-Day EMA: $290.00 | 20-Day SMA Pivot: $290.44 | 30-Day Resistance Ceiling: $295.03 (3.09% below) | 14-Day RSI: 46.7 (NEUTRAL CONSOLIDATION (46.7)) | 30-Day Trading Corridor: 8.19% span. $ABBV currently registers a Saku Momentum Pulse score of 64/100 and a Fundamental Health score of 74/100.
Why is $ABBV (AbbVie Inc.) moving and what is the bull vs. bear thesis?
Bull Thesis: Value and mean-reversion buyers in AbbVie Inc. ($ABBV) are monitoring the $272.70 30-day mechanical support floor (spot price at $286.20 sits 4.72% above support with 14-day RSI at 46.7 (NEUTRAL CONSOLIDATION (46.7))). Reclaiming the 10-day EMA ($290.00) and 20-day SMA pivot ($290.44) is the primary technical trigger to ignite a move back toward the $295.03 resistance ceiling. Bear Thesis: $ABBV (AbbVie Inc.) is currently trading below its 20-day simple moving average ($290.44) after a +2.43% 30-day move. If buyers fail to defend the 30-day mechanical support floor at $272.70 (4.72% above current spot), negative dealer gamma hedging can accelerate downside discovery toward the lower end of its 52-week range ($190.75).
What are $ABBV's key fundamentals, 52-week range, and upcoming catalysts?
AbbVie Inc. ($ABBV) trades with a market cap of $505.75B, a P/E ratio of 48.90x, and a 52-week range of $190.75 to $302.93. Next scheduled earnings window for AbbVie Inc. ($ABBV): 2026-10-30. Latest tracked headline from 247wallst.com: "$500,000 in AbbVie and Gilead Could Pay More Than $11,000 a Year in Dividends".